Axogen, Inc. Appoints William Burke to Board of Directors
July 11 2022 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that, effective July 11, 2022, William
Burke has been appointed to its Board of Directors and will serve
as chair of the Audit Committee. Mr. Burke is a recognized finance
leader in the medical technology industry with more than 25 years
of experience in senior leadership positions, including at
Haemonetics, Medtronic, and Covidien.
“Bill is an excellent addition to our board and brings a depth
of finance, business development, and investor relations
experience,” commented Karen Zaderej, chairman, CEO, and president.
“He has a long history of successful execution helping to bring
forward medical solutions that improve patient outcomes and quality
of life, which is fully aligned with the Axogen mission.”
Burke was the executive vice president, chief financial officer
of Haemonetics Corporation from August 2016 to June 2022 with
responsibility for the global finance organization including
investor relations. From July 2014 to July 2016, Burke served as
chief integration officer and vice president, Integration for
Medtronic plc and was a member of its executive committee. In that
role, he was responsible for ensuring the successful integration of
Medtronic with Covidien plc following its acquisition by Medtronic.
Prior to joining Medtronic, Burke spent more than 20 years in
finance and business development leadership roles at Covidien,
including chief financial officer for Covidien Europe based in
Zurich, vice president of Corporate Strategy and Portfolio
Management and vice president of Financial Planning and Analysis.
He also previously held key positions within Tyco Healthcare,
including the financial controller of Valleylab, managing director
of the Covidien Group in Switzerland, and international controller.
He began his career as an auditor with KPMG. He currently serves on
the board of directors of MiroMatrix (NASDAQ CM: MIRO). He received
his Bachelor of Science degree in Business Administration from
Bryant College.
“I am honored to join the Axogen Board of Directors and
contribute to the company’s mission of returning nerve function and
quality of life to patients with peripheral nerve injuries,” said
Burke. “Axogen is leading the nerve repair industry with an
innovative and comprehensive suite of surgical solutions. The
potential to help even more nerve repair patients is exciting and I
look forward to being a part of it.”
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa ECM coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, Germany, the United Kingdom, Spain,
South Korea, and several other countries.
Contact:Axogen, Inc.Ed Joyce, Director,
Investor Relationsejoyce@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024